SPARC Sun Pharma Advanced Research Company Ltd Major investments or disinvestments Announcement 2023 - Enrollment Completed in Phase 2 Study of Vodobatinib for Early Parkinsons Disease SPARC has completed the enrollment of 506 patients in a Phase 2 study of Vodobatinib for early Parkinsons disease..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Sun Pharma Advanced Research Company Ltd